Acromegaly - Pipeline Review, H2 2016

Published: Sep, 2016 | Pages: 91 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Acromegaly - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Acromegaly - Pipeline Review, H2 2016', provides an overview of the Acromegaly pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Acromegaly, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acromegaly and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Acromegaly
- The report reviews pipeline therapeutics for Acromegaly by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Acromegaly therapeutics and enlists all their major and minor projects
- The report assesses Acromegaly therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Acromegaly

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Acromegaly
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Acromegaly pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Acromegaly Overview 8
Therapeutics Development 9
Pipeline Products for Acromegaly - Overview 9
Pipeline Products for Acromegaly - Comparative Analysis 10
Acromegaly - Therapeutics under Development by Companies 11
Acromegaly - Therapeutics under Investigation by Universities/Institutes 12
Acromegaly - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Acromegaly - Products under Development by Companies 16
Acromegaly - Products under Investigation by Universities/Institutes 17
Acromegaly - Companies Involved in Therapeutics Development 18
Aegis Therapeutics, LLC 18
Amryt Pharma plc 19
Antisense Therapeutics Limited 20
Chiasma, Inc. 21
Crinetics Pharmaceuticals, Inc. 22
DexTech Medical AB 23
Foresee Pharmaceuticals, LLC 24
Glide Pharmaceutical Technologies Limited 25
Ionis Pharmaceuticals, Inc. 26
Ipsen S.A. 27
Italfarmaco S.p.A. 28
Midatech Pharma Plc 29
Novartis AG 30
Peptron, Inc. 31
Strongbridge Biopharma plc 32
Sun Pharma Advanced Research Company Ltd. 33
Acromegaly - Therapeutics Assessment 34
Assessment by Monotherapy Products 34
Assessment by Target 35
Assessment by Mechanism of Action 37
Assessment by Route of Administration 39
Assessment by Molecule Type 41
Drug Profiles 43
AP-102 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
atesidorsen sodium - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
COR-005 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
FP-002 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
IONIS-GHRLRx - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
ITF-2984 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
L-779976 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
octreotide acetate - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
octreotide acetate - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
octreotide acetate - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
octreotide acetate long acting - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
octreotide acetate SR - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
octreotide acetate SR - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
octreotide SR - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
pasireotide ER - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
Small Molecules to Activate Somatostatin Receptor Type 4 for Polycystic Kidney Disease, Acromegaly and Neuroendocrine Tumors - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
Somadex - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
SXN-101959 - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
Acromegaly - Dormant Projects 77
Acromegaly - Discontinued Products 78
Acromegaly - Product Development Milestones 79
Featured News & Press Releases 79
Jul 27, 2016: Positive Results Achieved from Interim Analysis of ATL1103 Higher Dose Study 79
Jul 13, 2016: ATL1103 Patent Update 80
Jun 28, 2016: Glide Technologies announces successful clinical proof-of-concept study 81
Jun 14, 2016: Chiasma Announces Corporate Restructuring Plan and Provides Regulatory Update Regarding Mycapssa 82
Jun 01, 2016: Antisense provides update on ATL1103 clinical trials 82
May 31, 2016: Strongbridge Biopharma plc Announces Presentation of COR-005 Data at the European Congress of Endocrinology 83
May 19, 2016: Glide Technologies Initiates Clinical Proof-of-Concept Study with Novel Octreotide Solid Dose Formulation Delivered via Needle-Free SDI 84
May 12, 2016: Orphan Drug designation from FDA for ATL1103 in Acromegaly 84
Apr 26, 2016: Midatech Pharma announces positive pharmacokinetic data with Q-Octreotide 85
Apr 18, 2016: Chiasma Provides Update Regarding FDA's Complete Response Letter for Mycapssa New Drug Application 85
Apr 15, 2016: FDA Issues Complete Response Letter for Mycapssa New Drug Application 86
Mar 14, 2016: Chiasma Initiates Phase 3 Trial to Support European Registration of Octreotide Capsules for Patients with Acromegaly 86
Nov 03, 2015: Strongbridge Biopharma Announces Data Presentation at the Society for Endocrinology BES 2015 Conference 87
Sep 09, 2015: ATL1103 Higher Dose Study-Dosing Commenced 88
Aug 17, 2015: Chiasma Announces FDA Acceptance For Filing of New Drug Application for Octreotide Capsules in Acromegaly 88
Appendix 90
Methodology 90
Coverage 90
Secondary Research 90
Primary Research 90
Expert Panel Validation 90
Contact Us 90
Disclaimer 91

List of Tables

Number of Products under Development for Acromegaly, H2 2016 9
Number of Products under Development for Acromegaly - Comparative Analysis, H2 2016 10
Number of Products under Development by Companies, H2 2016 11
Number of Products under Investigation by Universities/Institutes, H2 2016 12
Comparative Analysis by Late Stage Development, H2 2016 13
Comparative Analysis by Clinical Stage Development, H2 2016 14
Comparative Analysis by Early Stage Development, H2 2016 15
Products under Development by Companies, H2 2016 16
Products under Investigation by Universities/Institutes, H2 2016 17
Acromegaly - Pipeline by Aegis Therapeutics, LLC, H2 2016 18
Acromegaly - Pipeline by Amryt Pharma plc, H2 2016 19
Acromegaly - Pipeline by Antisense Therapeutics Limited, H2 2016 20
Acromegaly - Pipeline by Chiasma, Inc., H2 2016 21
Acromegaly - Pipeline by Crinetics Pharmaceuticals, Inc., H2 2016 22
Acromegaly - Pipeline by DexTech Medical AB, H2 2016 23
Acromegaly - Pipeline by Foresee Pharmaceuticals, LLC, H2 2016 24
Acromegaly - Pipeline by Glide Pharmaceutical Technologies Limited, H2 2016 25
Acromegaly - Pipeline by Ionis Pharmaceuticals, Inc., H2 2016 26
Acromegaly - Pipeline by Ipsen S.A., H2 2016 27
Acromegaly - Pipeline by Italfarmaco S.p.A., H2 2016 28
Acromegaly - Pipeline by Midatech Pharma Plc, H2 2016 29
Acromegaly - Pipeline by Novartis AG, H2 2016 30
Acromegaly - Pipeline by Peptron, Inc., H2 2016 31
Acromegaly - Pipeline by Strongbridge Biopharma plc , H2 2016 32
Acromegaly - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2016 33
Assessment by Monotherapy Products, H2 2016 34
Number of Products by Stage and Target, H2 2016 36
Number of Products by Stage and Mechanism of Action, H2 2016 38
Number of Products by Stage and Route of Administration, H2 2016 40
Number of Products by Stage and Molecule Type, H2 2016 42
Acromegaly - Dormant Projects, H2 2016 77
Acromegaly - Discontinued Products, H2 2016 78